MedDEV Programs
Respen-A
Respen-A utilizes the ingredient reserpine, delivered via a topical disc, for the homeopathic treatment of the symptoms of impaired communication, impaired social interaction and disruptive repetitive behaviors such as associated with autism spectrum disorders. Respen-A is currently marketed as a compounded prescription.
AM4
Preliminary work with AM4 shows promise of being an effective treatment for multiple sclerosis, depression, fibromyalgia, erectile dysfunction, and memory impairment. The mechanism of action is unknown but appears to stimulate monoamine oxidase-A (MAO-A) gene expression and to reverse the inhibitory effects of alanine on MAO-A. MAO-A activity is necessary for the production of the catecholamine and indoleamine physiologically active aldehyde metabolites that are necessary for neurotransmission.
EDL1
EDL1 is a proprietary transdermal solution of reserpine for the treatment of depression and depressive disorders such as bipolar disorder. EDL1 has been shown in a preliminary pilot study to be very effective in alleviating the symptoms of depression within 48 hours of the first dose. Anecdotal data has also shown it to be effective in refractory depression, bipolar disorder and alcoholism.
